Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib.
Christian BrieghelKathrine AarupMathias Husted TorpMichael Asger AndersenChristina W YdeXin TianAdrian WiestnerInhye E AhnCarsten Utoft NiemannPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
In this study, single-hit TP53 defines a distinct subgroup of patients with an excellent long-term response to single-agent ibrutinib, whereas multi-hit TP53 is independently associated with shorter PFS. These results warrant further investigations on prognostication and management of multi-hit TP53 CLL.See related commentary by Bomben et al., p. 4462.